Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.60 |
| ▸ | TSHR | P16473 | 3/20 | 0.52 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.52 |
| ▸ | GABRR1 | P24046 | 2/20 | 0.48 |
| ▸ | LTA4H | P09960 | 1/20 | 0.42 |
| ▸ | BLM | P54132 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | CA12 | O43570 | 2/20 | 0.39 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.39 |
| ▸ | CA7 | P43166 | 1/20 | 0.39 |
| ▸ | CA9 | Q16790 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1835136 | 1.00 | CYP1A2 (0.60) | CYP1A2TSHRSLC1A1GABRR1LTA4H | |
| SCHEMBL1835138 | 1.00 | CYP1A2 (0.60) | CYP1A2TSHRSLC1A1GABRR1LTA4H | |
| SCHEMBL233224 | 0.85 | LTA4H (0.56) | CYP1A2TSHRSLC1A1GABRR1LTA4H | |
| SCHEMBL3595528 | 0.84 | CYP1A2 (0.62) | CYP1A2SLC1A1GABRR1LTA4HBLM | |
| Hydrochloric Acid SCHEMBL1228512 | 0.84 | LTA4H (0.55) | CYP1A2TSHRSLC1A1GABRR1LTA4H | |
| SCHEMBL14360056 | 0.84 | LTA4H (0.55) | CYP1A2TSHRSLC1A1GABRR1LTA4H | |
| SCHEMBL12951358 | 0.82 | TSHR (0.52) | CYP1A2TSHRSLC1A1MEN1KMT2A | |
| SCHEMBL265551 | 0.82 | TSHR (0.52) | CYP1A2TSHRSLC1A1MEN1KMT2A | |
| SCHEMBL11062326 | 0.82 | TSHR (0.52) | CYP1A2TSHRSLC1A1MEN1KMT2A | |
| SCHEMBL16300949 | 0.82 | TSHR (0.52) | CYP1A2TSHRSLC1A1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240018110-A1 | RADIOLABELED COMPOUNDS TARGETING THE PROSTATE-SPECIFIC MEMBRANE ANTIGEN | ALPHA-9 ONCOLOGY INC. (CA) | 2024-01-18 | — | — | US | disclosed |
| US-9695112-B2 | Method for synthesizing optically active α-amino acid using chiral metal complex comprising axially chiral N-(2-acylaryl)-2-[5,7-dihydro-6H-dibenzo[c,e]azepin-6-yl] acetamide compound and amino acid | HAMARI CHEMICALS, LTD. (JP) | 2017-07-04 | — | — | US | disclosed |
| US-20160237043-A1 | KDM1A INHIBITORS FOR THE TREATMENT OF DISEASE | IMAGO BIOSCIENCES, INC. | 2016-08-18 | — | — | US | disclosed |
| US-20160102045-A1 | METHOD FOR SYNTHESIZING OPTICALLY ACTIVE a-AMINO ACID USING CHIRAL METAL COMPLEX COMPRISING AXIALLY CHIRAL N-(2-ACYLARYL)-2-[5,7-DIHYDRO-6H-DIBENZO[c,e]AZEPIN-6-YL] ACETAMIDE COMPOUND AND AMINO ACID | HAMARI CHEMICALS, LTD. (JP) | 2016-04-14 | — | — | US | disclosed |
| US-8580823-B2 | Piperidine renin inhibitors | VITAE PHARMACEUTICALS, INC. (US) | 2013-11-12 | — | — | US | disclosed |
| US-7998965-B2 | Glutamate aggrecanase inhibitors | WYETH LLC (US) | 2011-08-16 | — | — | US | disclosed |
| EP-2230312-A1 | Probe compound for detecting and isolating enzymes and means and methods using the same | Helmholtz-Zentrum für Infektionsforschung GmbH (DE) | 2010-09-22 | — | — | EP | disclosed |
| US-20100010012-A1 | GLUTAMATE AGGRECANASE INHIBITORS | WYETH (US) | 2010-01-14 | — | — | US | disclosed |
| US-7553873-B2 | Glutamate aggrecanase inhibitors | WYETH (US) | 2009-06-30 | — | — | US | disclosed |
| US-7528127-B2 | Short-acting benzodiazepines | CENES LIMITED (GB) | 2009-05-05 | — | — | US | disclosed |
| US-7485635-B2 | Short-acting benzodiazepines | CENES LIMITED (GB) | 2009-02-03 | — | — | US | disclosed |
| US-7473689-B2 | Short-acting benzodiazepines | CENES LIMITED (GB) | 2009-01-06 | — | — | US | disclosed |
| US-7435730-B2 | Short-acting benzodiazepines | CENES LIMITED (GB) | 2008-10-14 | — | — | US | disclosed |
| US-20070135420-A1 | e.g. Methyl 3-[(4S)-8-bromo-1-methyl-6-(2-pyridinyl)-4H-pyrro[1,2-a][1,4]benzodiazepin-4-yl]propanoate; GABAA (gamma aminobutiric acid) receptor antagonist; sedative-hypnotic, anxiolytic, muscle relaxant and anticonvulsant; anesthesia | CENES LIMITED (GB) | 2007-06-14 | — | — | US | disclosed |
| US-20070135419-A1 | Short-acting benzodiazepines | CENES LIMITED (GB) | 2007-06-14 | — | — | US | disclosed |
| US-20070135421-A1 | Short-acting benzodiazepines | CENES LIMITED (GB) | 2007-06-14 | — | — | US | disclosed |
| US-20070093475-A1 | Short-acting benzodiazepines | CENES LIMITED (GB) | 2007-04-26 | — | — | US | disclosed |
| US-20070043066-A1 | Glutamate aggrecanase inhibitors | WYETH (US) | 2007-02-22 | — | — | US | disclosed |
| US-7160880-B1 | Short-acting benzodiazepines | CENES LIMITED (GB) | 2007-01-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100010012-A1 | GLUTAMATE AGGRECANASE INHIBITORS | ADAMTS5, ADAMTS1, ADAMTS7 | CYP1A2 4799/4885TSHR 3570/4885SLC1A1 60/4885 |
| US-20070093475-A1 | Short-acting benzodiazepines | GABRA5, GABRA1, GABRA6 | CYP1A2 39/4885TSHR 581/4885SLC1A1 425/4885 |
| US-20070135420-A1 | e.g. Methyl 3-[(4S)-8-bromo-1-methyl-6-(2-pyridinyl)-4H-pyrro[1,2-a][1,4]benzodiazepin-4-yl]propanoate; GABAA (gamma aminobutiric acid) receptor antagonist; sedative-hypnotic, anxiolytic, muscle relaxant and anticonvulsant; anesthesia | GABRA1, GABRA2, GABRA6 | CYP1A2 60/4885TSHR 495/4885SLC1A1 389/4885 |
| US-20240018110-A1 | RADIOLABELED COMPOUNDS TARGETING THE PROSTATE-SPECIFIC MEMBRANE ANTIGEN | KLK3, FOLH1, TMEM14C | CYP1A2 4564/4885TSHR 1149/4885SLC1A1 1090/4885 |
| US-20070135419-A1 | Short-acting benzodiazepines | GABRA5, GABRA1, GABRA6 | CYP1A2 39/4885TSHR 581/4885SLC1A1 425/4885 |
| US-20160102045-A1 | METHOD FOR SYNTHESIZING OPTICALLY ACTIVE a-AMINO ACID USING CHIRAL METAL COMPLEX COMPRISING AXIALLY CHIRAL N-(2-ACYLARYL)-2-[5,7-DIHYDRO-6H-DIBENZO[c,e]AZEPIN-6-YL] ACETAMIDE COMPOUND AND AMINO ACID | AADAT, ALDH7A1, BCAT1 | CYP1A2 857/4885TSHR 4329/4885SLC1A1 111/4885 |
| US-20160237043-A1 | KDM1A INHIBITORS FOR THE TREATMENT OF DISEASE | KDM1B, KDM1A, KDM2A | CYP1A2 3176/4885TSHR 4247/4885SLC1A1 3052/4885 |
| US-20070135421-A1 | Short-acting benzodiazepines | GABRA5, GABRA1, GABRA6 | CYP1A2 39/4885TSHR 581/4885SLC1A1 425/4885 |
| US-20070043066-A1 | Glutamate aggrecanase inhibitors | ADAMTS5, ADAMTS1, ADAMTS7 | CYP1A2 4799/4885TSHR 3570/4885SLC1A1 60/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.